Why the study?
Does overexpressing IGF-1R in the endothelium improve endothelial function and repair in mice?
Does overexpressing IGF-1R in the endothelium improve endothelial function and repair in mice?
Absolute Event Rate: 48% vs 106%
p-value: p=<0.05
Manipulating IGF-1R in the endothelium reduces NO bioavailability but enhances in situ endothelium regeneration, suggesting a potential strategy to treat disorders of vascular growth and repair.
We recently demonstrated that reducing IGF-1 receptor (IGF-1R) numbers in the endothelium enhances nitric oxide (NO) bioavailability and endothelial cell insulin sensitivity. In the present report, we aimed to examine the effect of increasing IGF-1R on endothelial cell function and repair. To examine the effect of increasing IGF-1R in the endothelium, we generated mice overexpressing human IGF-1R in the endothelium (human IGF-1R endothelium-overexpressing mice [hIGFREO]) under direction of the Tie2 promoter enhancer. hIGFREO aorta had reduced basal NO bioavailability (percent constriction to N(G)-monomethyl-l-arginine [mean (SEM) wild type 106% (30%); hIGFREO 48% (10%)]; P < 0.05). Endothelial cells from hIGFREO had reduced insulin-stimulated endothelial NO synthase activation (mean [SEM] wild type 170% [25%], hIGFREO 58% [3%]; P = 0.04) and insulin-stimulated NO release (mean [SEM] wild type 4,500 AU [1,000], hIGFREO 1,500 AU [700]; P < 0.05). hIGFREO mice had enhanced endothelium regeneration after denuding arterial injury (mean [SEM] percent recovered area, wild type 57% [2%], hIGFREO 47% [5%]; P < 0.05) and enhanced endothelial cell migration in vitro. The IGF-1R, although reducing NO bioavailability, enhances in situ endothelium regeneration. Manipulating IGF-1R in the endothelium may be a useful strategy to treat disorders of vascular growth and repair.
No takes yet. Share an insight, caveat, or question.
Imrie et al. (2012) studied Endothelial dysfunction. Endothelium-targeted overexpression of human IGF-1R (hIGFREO) vs. Wild-type littermates was evaluated on Basal NO bioavailability (percent constriction to L-NMMA) (p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: